A Phase 3 interventional study of Venofer 200 MG Per 10 ML Injection and Ferrous sulfate in Iron Deficiency Anemia of Pregnancy, sponsored by Arrowhead Regional Medical Center. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Arrowhead Regional Medical Center · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing iron sucrose in Anemia — 1 open to participants now, 1 under way, none of them phase 3. iron sucrose · Anemia.
Among the 29 studies testing iron sucrose in Anemia, this one has the largest enrollment, is one of 2 that started in 2023, is one of 9 in phase 3, and was the 27th registered.
1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.
Browse Anemia studies →1 of the 29 studies testing iron sucrose in Anemia is open now, in 1 country. Recruiting first, the newest first:
Fox Chase Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
iron sucrose: first FDA approval 2000 (VENOFER). What it is approved for, and how studies give it, is on its page →
Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 9 · Phase 4 10
First in 2001; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 518 is above the median of 117 across 1,338 interventional studies indexed under Anemia.
Median enrollment 80 across the 29 interventional studies. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 29 have an industry lead sponsor. The 10 most frequent:
Arrowhead Regional Medical Center is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Arrowhead Regional Medical Center has 1 study filed under Anemia — fewer than ten, so there is no comparison to draw.
1 of the studies testing iron sucrose in Anemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05800600Fox Chase Cancer CenterIron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy | 2027-02-01 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies testing iron sucrose in Anemia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to assess whether administering intravenous iron early in pregnancy, compared to standard oral iron treatment, can enhance hemoglobin levels before delivery and reduce the need for blood transfusions in patients with iron deficiency anemia. Patients diagnosed with iron deficiency anemia were randomly assigned to receive either oral or intravenous iron. Before treatment initiation, patients completed a symptom questionnaire baseline hemoglobin, and ferritin levels were measured. Follow-up visits occurred four weeks later and at 24 to 28 weeks gestation, involving reassessment of symptoms, laboratory testing, and monitoring of treatment adherence. Final hemoglobin levels were determined before delivery, and data on the need for blood transfusion at delivery were recorded.
Iron deficiency anemia is a prevalent health concern affecting approximately a quarter of the global population. In specific high-risk subgroups such as pregnancy, the occurrence of anemia is even higher. This condition is associated with adverse outcomes such as increased risks of blood transfusion, longer hospital stays, slower recovery, and depression, along with pregnancy risks such as preterm birth and low birth weight. Furthermore, infants born to iron-deficient mothers are at risk for delayed childhood growth and cognitive development. Preoperative optimization is crucial for improving clinical outcomes, as iron deficiency anemia accounts for over 80% of anemia cases in these patients.
Traditionally, oral (PO) iron supplementation has been the standard approach recommended by the American College of Obstetrics and Gynecology (ACOG) for preventing and addressing iron deficiency due to its simplicity and cost-effectiveness. However, it is marred by poor adherence to therapy and a high incidence of gastrointestinal side effects. While numerous publications have documented the safety and efficacy of intravenous (IV) iron, its utilization remains limited. Currently, IV iron is primarily reserved for patients who exhibit intolerance or an inadequate response to oral therapy. At our institution, we have taken proactive steps by administering IV iron infusions to many of our patients at an earlier gestational age, given the high rate of non-compliance with oral iron therapy. Our hypothesis proposes that individuals with iron deficiency anemia, defined as a serum ferritin level of less than 30 ng/mL (with 92% sensitivity and 98% specificity compared to hemoglobin (Hgb) levels), who receive IV iron infusions, will achieve higher Hgb levels upon admission and experience reduced rates of blood transfusions.
This study aims to assess the impact of IV iron infusions on pregnant patients with iron deficiency anemia. We hope that implementing this study will help improve overall population health. We hypothesize that individuals with iron deficiency anemia who receive IV iron infusions will attain higher Hgb levels at the time of admission and experience reduced rates of blood transfusions at the time of delivery.
After obtaining the patient's consent, they will be allocated into either of the two treatment options. All odd numbers will be in the oral iron group and even numbers enrolled into the IV iron group. We intend to administer Ferrous sulfate 325 mg orally every other day on an empty stomach with lemon/orange water, as numerous randomized control trials have demonstrated that increasing the iron dose does not lead to improved efficacy. Venofer 200 mg will be given every other day until the patient reaches their calculated iron deficit. The dose of IV iron will be calculated according to the Ganzoni formula: total iron dose (mg) = body weight (kg) x (target Hgb - baseline Hgb (g/dL)) × 0.24 + 500 mg. Our target Hgb will be 11.0 g/dL.
Patients will be given a symptom questionnaire at the time of enrollment to fill out. We will analyze the patient's ferritin, iron, total iron binding capacity (TIBC), Hgb level, mean corpuscular volume (MCV), and Hgb electrophoresis, which are routinely obtained on the first visit with prenatal labs. Four weeks after initiating treatment, patients will fill out a symptom and side effect questionnaire, and if on PO iron, their compliance will be assessed. Complete blood count (CBC) and iron studies will be repeated at that time. Other patient information such as admission CBC, post-delivery CBC, height, weight, body mass index (BMI), age, parity, gestational age at delivery, quantitative blood loss, route of delivery, need for blood transfusion, number of IV iron infusions, fetal birth weight, and antepartum/intrapartum/postpartum complications such as diabetes, preeclampsia/eclampsia, chorioamnionitis, and hemorrhage, etc., neonatal intensive care unit (NICU) admission as well as Edinburgh depression screening results, will be obtained from medical records. This information will be used for secondary outcomes analysis and to ensure there are no confounding factors. Statistical comparisons between groups will be performed using the two-way T-test followed by Tukey's test, or post hoc Student-Newman-Keuls tests. A P \< .05 will be considered a statistically significant difference among groups.
The criteria were revised on the registry on Nov 9, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Venofer 200 mg will be given every other day until the patient reaches their calculated in deficit dose. The does of IV iron will be calculated according to the Ganzoni formula: total iron dose (mg) = body weight (kg) x (target Hgb - baseline Hgb (g/dL)) × 0.24 + 500 mg.14 Our target Hgb will be 11.0 g/dL. The determination of the treatment duration and dosage will be based on the calculation of the iron deficit.
Drug: Venofer 200 MG Per 10 ML Injection
Ferrous sulfate 325 mg orally every other day on an empty stomach with lemon/orange water until delivery.
Drug: Ferrous sulfate
200 mg IV every 2 days until the targeted dose
Also known as: Iron sucrose
Take 1 tablet every other day with lemon/orange juice
Hemoglobin difference
Change in hemoglobin level after intervention, larger difference mean more improvement in Hgb
Time frame: Hemoglobin level obtained prior to treatment and then 4 weeks later
Ferritin difference
Change in ferritin level after intervention, larger difference mean more improvement in ferritin level
Time frame: Ferritin level obtained prior to treatment and then 4 weeks later
Preterm delivery
Comparing hemoglobin levels to gestational age at delivery
Time frame: At the time of delivery
Depression
Edinburgh postnatal depression scale at first prenatal visit and postpartum. 10 questions with total score between 0-30. Higher score indicated increase risk for depression.
Time frame: Duration of the pregnancy (up to 40 weeks) and up to 2 months postpartum
Birthweight
Comparing birthweight to hemoglobin levels at time of admission
Time frame: At time of delivery
Pre-delivery Hemoglobin
Comparing pre-delivery hemoglobin levels
Time frame: Obtained at time of delivery
Symptoms
Comparing number of anemia symptoms before and after treatment. There are 11 anemia symptoms on the questionnaire. Using a Likert scale from 0 (no symptoms) to 5 (severe symptoms) patient mark each one. The score is totaled up and can range from 0-55.
Time frame: 4 weeks
Rates of blood transfusion
Comparing rates of blood transfusion at time of delivery between the 2 groups. The number of units transfused will be collected and compared among the groups
Time frame: At time of delivery until 6 weeks postpartum
Persistent anemia
Comparing the number of patients with Hgb \< 10.5 after intervention
Time frame: 4 weeks
Treatment adherence
Treatment adherence was assessed differently according to the assigned treatment group. In the oral iron group, adherence was evaluated using patient-reported responses to a follow-up survey regarding compliance with the prescribed alternate-day ferrous sulfate regimen. In the IV iron group, adherence was determined by reviewing infusion records to assess whether participants received the prescribed number of iron sucrose infusions based on their calculated iron deficit.
Time frame: 4 weeks
Adverse effects
Medication-related adverse effects were assessed using a patient-reported survey. Participants were asked about symptoms or side effects experienced during treatment.
Time frame: 4 weeks
Blood loss
Estimated maternal blood loss (mL) at the time of delivery, as documented in the medical record.
Time frame: At the time of delivery until 5 days postpartum
. Mode of delivery
Mode of delivery, categorized as vaginal delivery or cesarean delivery, as documented in the medical record.
Time frame: At the time of delivery
Apgar scores
Neonatal Apgar scores at 1 and 5 minutes after birth, as documented in the medical record. Range 0 to 10
Time frame: At time of delivery, 1 and 5 minutes
NICU admission
Admission to the neonatal intensive care unit (NICU) following delivery, recorded as yes or no.
Time frame: At the time of delivery until 5 days postpartum
Neonatal hemoglobin
Neonatal hemoglobin concentration (g/dL), as measured after birth and documented in the medical record.
Time frame: At the time of delivery until 5 days postpartum
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2023 to primary completion in Sep 2025, 21 months.
Of 50 non-industry phase 3 interventional studies under Anemia, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 21 months is below that.
Counting every sponsor, half of 148 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Dec 2025 → Sep 2025 and completion Dec 2025 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iron sucrose
Arrowhead Regional Medical Center